We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Galapagos Subsidiary BioFocus Collaborate with Senexis
News

Galapagos Subsidiary BioFocus Collaborate with Senexis

Galapagos Subsidiary BioFocus Collaborate with Senexis
News

Galapagos Subsidiary BioFocus Collaborate with Senexis

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Galapagos Subsidiary BioFocus Collaborate with Senexis"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Senexis Limited and Galapagos NV have announced that they have expanded their collaboration to optimise Senexis' inhibitors of amyloid-induced toxicity and neuroinflammation for the treatment of Alzheimer's disease. 

Galapagos will receive research fees for the medicinal chemistry services provided to Senexis. 

The collaboration aims to significantly advance Senexis' small molecule Alzheimer's programs towards the clinic and is unrelated to Galapagos' own Alzheimer's disease targets program.
 
"We are delighted to continue our successful collaboration with BioFocus," said David Scopes, Senexis' Chief Scientific Officer. 

"We have now made significant progress with our small molecule programmes, so that our lead series now demonstrate similar potency to peptides when inhibiting amyloid-induced toxicity."
 
Onno van de Stolpe, Galapagos' CEO, commented, "We are pleased that BioFocus has been able to help advance Senexis' Alzheimer's program, and offering our medicinal chemistry expertise should further help to accelerate their development program."

Advertisement